Akebia Therapeutics Inc (AKBA)
1.37
+0.07
(+5.38%)
USD |
NASDAQ |
May 03, 16:00
1.42
+0.05
(+3.65%)
After-Hours: 20:00
Akebia Therapeutics Revenue (Quarterly): 56.20M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 56.20M |
| September 30, 2023 | 42.05M |
| June 30, 2023 | 56.38M |
| March 31, 2023 | 40.13M |
| December 31, 2022 | 55.78M |
| September 30, 2022 | 48.71M |
| June 30, 2022 | 126.36M |
| March 31, 2022 | 61.70M |
| December 31, 2021 | 57.68M |
| September 30, 2021 | 48.76M |
| June 30, 2021 | 52.91M |
| March 31, 2021 | 52.30M |
| December 31, 2020 | 56.04M |
| September 30, 2020 | 59.99M |
| June 30, 2020 | 90.14M |
| Date | Value |
|---|---|
| March 31, 2020 | 88.48M |
| December 31, 2019 | 69.56M |
| September 30, 2019 | 91.98M |
| June 30, 2019 | 100.80M |
| March 31, 2019 | 72.67M |
| December 31, 2018 | 59.85M |
| September 30, 2018 | 53.17M |
| June 30, 2018 | 48.79M |
| March 31, 2018 | 45.93M |
| December 31, 2017 | 90.56M |
| September 30, 2017 | 41.28M |
| June 30, 2017 | 28.52M |
| March 31, 2017 | 20.86M |
| December 31, 2016 | 1.535M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
40.13M
Minimum
Mar 2023
126.36M
Maximum
Jun 2022
66.10M
Average
56.38M
Median
Jun 2023
Revenue (Quarterly) Benchmarks
| Ocugen Inc | 6.036M |
| Aquestive Therapeutics Inc | 13.21M |
| SELLAS Life Sciences Group Inc | -- |
| Protagonist Therapeutics Inc | 60.00M |
| Stoke Therapeutics Inc | 2.802M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 0.614M |
| Total Expenses (Quarterly) | 54.82M |
| EPS Diluted (Quarterly) | 0.0032 |
| Enterprise Value | 278.90M |
| Gross Profit Margin (Quarterly) | 66.79% |
| Profit Margin (Quarterly) | 1.09% |
| Earnings Yield | -20.20% |
| Normalized Earnings Yield | -19.93 |